Micro Mature Active

强生公司 (JNJ) 受益于增长管线以及在关键治疗领域的力量

成熟的叙事，报道稳定。

评分
0.4
动能
▲ 0.0
文章
34
来源
3

热门股

股票代码板块变动
JNJ
Healthcare+7.6%

情绪时间线

板块表现

事件时间线

七月 04, 2026
Johnson & Johnson Is Walking Away From a $100 Billion Obesity Market. … Neutral
六月 26, 2026
Why Johnson & Johnson Stock Popped on Friday Bullish
六月 22, 2026
How Johnson & Johnson (JNJ) Is Using U.S. Manufacturing Investment to Strengthen … Bullish
六月 19, 2026
Johnson & Johnson to Invest Over $1 Billion in Florida Contact Lens … Neutral
六月 16, 2026
J&J CEO says curing certain cancers within a decade is realistic Bullish
六月 14, 2026
Jim Cramer Explains Johnson & Johnson’s (JNJ) Shares Have Gained Bullish
六月 13, 2026
Is Johnson & Johnson (JNJ) A Good Stock To Buy Now? Bullish
六月 12, 2026
Johnson & Johnson Just Paid $1 Billion for a Technology That Could … Bullish
六月 10, 2026
Jim Cramer Applauds Johnson & Johnson’s “Great New Drug Profits, Triple-A Balance … Bullish
六月 05, 2026
Jim Cramer Highlights Johnson & Johnson Having No Big Patent Expirations Bullish
六月 02, 2026
Johnson & Johnson Hopes to Dethrone AbbVie's Biggest Growth Driver. Here's Why … Neutral
五月 29, 2026
Is Johnson & Johnson Stock Outperforming the Dow? Neutral
五月 22, 2026
Johnson & Johnson (JNJ) Unveils Next‑Gen Catheter for Coronary Artery Disease Bullish
五月 13, 2026
An unloved health-care stock gets a welcome nod in this AI-obsessed market Bullish
五月 05, 2026
Johnson & Johnson reaches a milestone for one of its most exciting … Bullish
五月 04, 2026
Johnson & Johnson’s (JNJ) Accelerating Growth Justifies the Higher Multiple Bullish
五月 03, 2026
Jim Cramer Shares Key Trend For Johnson & Johnson (JNJ) Shares Bullish
四月 26, 2026
Johnson & Johnson AGM: CEO Duato touts “catalyst year,” 5.3% sales growth … Bullish
四月 24, 2026
Is Johnson & Johnson (JNJ) a Buy on Sales Growth and Solid … Bullish
四月 14, 2026
Jim Cramer on Johnson & Johnson: “If It Gets Blasted, Try to … Bullish
四月 13, 2026
Johnson & Johnson (JNJ) is Gaining from Its Strong Innovative Medicine Growth Bullish
四月 10, 2026
Could Buying This Dividend Pharma Stock Today Set You Up for Life? Bullish
四月 08, 2026
We're exiting our position in a drug stock and initiating a stake … Bullish
三月 31, 2026
The Dividend King That's Raised Its Payout for 63 Consecutive Years Bullish

相关文章

Johnson & Johnson Just Paid $1 Billion for a Technology That Could Crack One of …

Nasdaq · 六月 12, 2026
Bearish

Johnson & Johnson (JNJ) Unveils Next‑Gen Catheter for Coronary Artery Disease

Yahoo Finance · 五月 22, 2026
Neutral

An unloved health-care stock gets a welcome nod in this AI-obsessed market

CNBC · 五月 13, 2026
Mixed

Johnson & Johnson AGM: CEO Duato touts “catalyst year,” 5.3% sales growth and $32B investment …

Yahoo Finance · 四月 26, 2026
Mixed

We're exiting our position in a drug stock and initiating a stake in a more …

CNBC · 四月 08, 2026
Mixed
🤖

AI概览

发生了什么：强生公司（JNJ）的增长得益于其创新的药物管线和在关键治疗领域的实力。Mar Vista Investment Partners 强调了强生公司的发展势头，而另一篇文章指出，该公司已连续 60 多年增加股息。此外，Jim Cramer's Charitable Trust 退出了其在百时美施贵宝的头寸，并开始持有强生公司的股份。

市场影响：这一叙事对强生公司和更广泛的制药行业具有看涨意义。强生公司多元化的业务模式和持续的股息增长使其成为一项有吸引力的投资，吸引了资金流入该股票。Jim Cramer's 投资组合的举动预示着对强生公司情绪的转变，可能会影响其他投资者。

接下来关注什么：投资者应密切关注强生公司定于 2023 年 7 月 19 日公布的第二季度财报，以评估其增长管线的进展。此外，监管机构对强生公司管线候选药物的决定，例如其 COVID-19 疫苗加强剂的潜在批准，将是该叙事演变的催化剂。最后，关注强生公司 2023 年 9 月的股息支付，持续的增长将进一步验证该公司强劲的财务健康状况。
AI概览（截至） 六月 26, 2026

时间线

首次发现三月 31, 2026
最后更新三月 31, 2026